Published in Lab Business Week, May 1st, 2005
The FDA has acknowledged that Biovail's Complete Response to the Tramadol ER Approvable Letter is a Class 2 response, which is therefore subject to a 6-month review. The FDA has also advised that, upon preliminary review, it is of the opinion that additional clinical trial data will be required.
Biovail's view is that the clinical data contained within the original NDA and the March 2005 Complete...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week